MARKET

PHVS

PHVS

Pharvaris N.V.
NASDAQ
27.35
-0.04
-0.15%
After Hours: 27.35 0 0.00% 17:13 03/27 EDT
OPEN
27.44
PREV CLOSE
27.39
HIGH
27.91
LOW
26.94
VOLUME
82.91K
TURNOVER
--
52 WEEK HIGH
29.80
52 WEEK LOW
11.51
MARKET CAP
1.78B
P/E (TTM)
-7.9763
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PHVS last week (0316-0320)?
Weekly Report · 5d ago
Is It Too Late To Consider Pharvaris (PHVS) After A 3.5x Three Year Surge?
Simply Wall St · 5d ago
Pharvaris (PHVS) Valuation Check After Strong One Year Return And Rich Price To Book Ratio
Simply Wall St · 03/20 22:15
Pharvaris announces publications of efficacy, safety evidence on deucrictibant
TipRanks · 03/20 10:55
Pharvaris reports Phase 2 CHAPTER-1 and RAPIDe-1 trial results for oral deucrictibant in hereditary angioedema
Reuters · 03/20 10:53
Pharvaris Announces Publication Of Data From Two Randomized Phase 2 Studies, CHAPTER-1 And RAPIDe-1, Evaluating Efficacy And Safety Of Deucrictibant For Prophylaxis And On-Demand Treatment Of HAE Attacks, In The Lancet Haematology
Benzinga · 03/20 10:53
Revolution, Ascendis, Arrowhead among RBC’s top M&A candidates in biotech
Seeking Alpha · 03/19 18:37
Pharvaris NV director Robert Glassman files initial beneficial ownership statement
Reuters · 03/18 18:24
More
About PHVS
Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.

Webull offers Pharvaris NV stock information, including NASDAQ: PHVS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PHVS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PHVS stock methods without spending real money on the virtual paper trading platform.